Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
-
- Hartmut Döhner
- 1Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany;
-
- Andrew H. Wei
- 2Department of Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia;
-
- Frederick R. Appelbaum
- 3University of Washington and the Fred Hutchinson Cancer Research Center, Seattle, WA;
-
- Charles Craddock
- 4Centre for Clinical Haematology, Queen Elizabeth Hospital, University of Birminham, Birmingham, UK;
-
- Courtney D. DiNardo
- 5Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;
-
- Hervé Dombret
- 6Department of Hematology, Saint-Louis Institute for Research, Université de Paris, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France;
-
- Benjamin L. Ebert
- 7Dana-Farber Cancer Institute, Boston, MA;
-
- Pierre Fenaux
- 8Service d’Hématologie Séniors, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France;
-
- Lucy A. Godley
- 9Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL;
-
- Robert P. Hasserjian
- 10Department of Pathology, Massachusetts General Hospital, Boston, MA;
-
- Richard A. Larson
- 11Department of Medicine and Comprehensive Cancer Center, University of Chicago, Chicago, IL;
-
- Ross L. Levine
- 12Human Oncology and Pathogenesis Program and Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;
-
- Yasushi Miyazaki
- 13Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan;
-
- Dietger Niederwieser
- 14University of Leipzig, Leipzig, Germany;
-
- Gert Ossenkoppele
- 15Department of Haematology, Amsterdam UMC, Location VU University Medical Center, Amsterdam, The Netherlands;
-
- Christoph Röllig
- 16Department of Internal Medicine I, University Hospital Carl Gustav Carus TU Dresden, Dresden, Germany;
-
- Jorge Sierra
- 17Hematology Department, Hospital Santa Creu i Sant Pau, Barcelona, Spain;
-
- Eytan M. Stein
- 18Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York;
-
- Martin S. Tallman
- 18Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York;
-
- Hwei-Fang Tien
- 19Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan;
-
- Jianxiang Wang
- 20Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China;
-
- Agnieszka Wierzbowska
- 21Department of Hematology, Medical University of Lodz, Lodz, Poland; and
-
- Bob Löwenberg
- 22Department of Hematology, Erasmus University Medical Center Rotterdam and Erasmus MC Cancer Institute, Rotterdam, The Netherlands
Description
<jats:title>Abstract</jats:title><jats:p>The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease classification, technological progress in genomic diagnostics and assessment of measurable residual disease, and the successful development of new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors. These advances have prompted this update that includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations.</jats:p>
Journal
-
- Blood
-
Blood 140 (12), 1345-1377, 2022-09-22
American Society of Hematology
- Tweet
Details 詳細情報について
-
- CRID
- 1360579820400466048
-
- ISSN
- 15280020
- 00064971
-
- Data Source
-
- Crossref
- KAKEN